Catalyst
Slingshot members are tracking this event:
Regeneron Pharmaceuticals (REGN) expecting cardiovascular outcome Praluent, antibody, for lowering LDL cholesterol, to report data in early 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 10, 2018
Occurred Source:
http://files.shareholder.com/downloads/REGN/5250934809x0x973882/17F54203-5B2A-42BF-AA7C-96AF38D6DB97/REGN_News_2018_3_10_General_Releases.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Praluent, Ldl Cholesterol
